Check for updates

OPEN ACCESS

APPROVED BY Frontiers Editorial Office, Frontiers Media SA, Switzerland

*CORRESPONDENCE Ji-Hao Zhou Zhoujihao@aliyun.com Chun Feng fengch8@qq.com

RECEIVED 03 July 2025 ACCEPTED 04 July 2025 PUBLISHED 15 July 2025

CITATION

Xiang Q-y, Zuo M, Zhou J-H and Feng C (2025) Correction: EBV-positive diffuse large B cell lymphoma secondary to activated phosphoinositide 3 kinase δ syndrome type 1 (APDS1): a case report and literature review. *Front. Immunol.* 16:1659197. doi: 10.3389/fimmu.2025.1659197

COPYRIGHT

© 2025 Xiang, Zuo, Zhou and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: EBV-positive diffuse large B cell lymphoma secondary to activated phosphoinositide 3 kinase δ syndrome type 1 (APDS1): a case report and literature review

Qiu-yuan Xiang¹, Min Zuo², Ji-Hao Zhou^{3*} and Chun Feng^{3*}

¹Department of Hematology, The Second Clinical Medical College of Jinan University, Shenzhen, China, ²Department of Pathology, Shenzhen People's Hospital (The Second Clinical Medical College of Jinan University; The First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, China, ³Department of Hematology, Shenzhen People's Hospital (The Second Clinical Medical College of Jinan University; The First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, China

KEYWORDS

activated phosphoinositide 3-kinase δ syndrome, Epstein-Barr virus, diffuse large B-cell lymphoma, Epstein-Barr virus-positive diffuse large B-cell lymphoma (EBV+ DLBCL), inborn error of immunity

A Correction on

EBV-positive diffuse large B cell lymphoma secondary to activated phosphoinositide 3 kinase δ syndrome type 1 (APDS1): a case report and literature review

By Xiang Q-y, Zuo M, Zhou J-H and Feng C (2025) *Front. Immunol.* 6:1583405. doi: 10.3389/fimmu.2025.1583405

Wrong affiliation, but not replacing with present address

Author "Min Zuo" was erroneously assigned to affiliation "Department of Pathology, The Second Clinical Medical College of Jinan University, Shenzhen, China".

The correct affiliation is "Department of Pathology, Shenzhen People's Hospital (The Second Clinical Medical College of Jinan University; The First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, China".

Authors "Ji-Hao Zhou and Chun Feng" were erroneously assigned to affiliation "Department of Hematology, The Second Clinical Medical College of Jinan University, Shenzhen, China".

The correct affiliation is "Department of Hematology, Shenzhen People's Hospital (The Second Clinical Medical College of Jinan University; The First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, China".

The original version of this article has been updated.

01

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.